Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations
| Autor: | Baochai Lin, Shaoran Fei, Xia Deng, Huafang Su, Hanbin Chen, Zhen Zheng, Congying Xie, Deyao Xie, Xiance Jin, Lihao Zhao |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Side effect
03 medical and health sciences Exon 0302 clinical medicine medicine Epidermal growth factor receptor Lung cancer Tyrosine kinase inhibitors biology Proportional hazards model business.industry Brain metastasis Bone metastasis medicine.disease respiratory tract diseases Oncology 030220 oncology & carcinogenesis Cancer research biology.protein business Non-small-cell lung cancer Tyrosine kinase 030217 neurology & neurosurgery Research Paper |
| Zdroj: | Journal of Cancer |
| ISSN: | 1837-9664 |
| DOI: | 10.7150/jca.16959 |
| Popis: | Background: Although superior clinical benefits of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer (NSCLC) had been reported with different sensitivity, the sensitivity of second-line TKIs in NSCLC patients with different EFGR mutations was unknown. The purpose of this study is to investigate the clinical outcome of second-line EGFR-TKIs in the treatment of NSCLC patients according to different EGFR genotypes. Methods: The treatment outcomes of 166 NSCLC patients with different EGFR mutations treated by second-line TKIs were retrospectively reviewed. The efficacy was evaluated with Pearson chi-square or Fisher's exact tests, Log-rank test and Cox proportional hazards model. Results: The disease control rate (DCR) and objective response rate (ORR) of enrolled NSCLC patients were 77.7% and 11.4%, respectively. The exon 19 deletion group had a significantly longer median progression-free survival (PFS) (6.7 vs. 4.5 months, P=0.002) and overall survival (OS) (13.7 vs. 11.7 months, P=0.02) compared with the exon 19 L858R mutation group for NSCLC patients, as well for patients with brain metastasis [PFS: (6.7 vs. 3.9 months, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|